{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:09:30Z","timestamp":1794924570342,"version":"4.9.1"},"reference-count":125,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100019450","name":"Verastem Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019450","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1136\/ijgc-2023-004610","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T11:00:39Z","timestamp":1692270039000},"page":"1331-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Low-grade serous ovarian cancer: expert consensus report on the state of the science"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct04095364","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03673124","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04931342","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04625270","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01461850","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04095364","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04931342","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04625270","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04575961","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03012620","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-9324","authenticated-orcid":false,"given":"Rachel N.","family":"Grisham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-3096","authenticated-orcid":false,"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-7934","authenticated-orcid":false,"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-1762","authenticated-orcid":false,"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie-Ming","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong-Kwok","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-2140","authenticated-orcid":false,"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004610_bb0010","article-title":"Trends of low-grade Serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0015","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade Serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004610_bb0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004610_bb0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0035","author":"WHO Classification of Tumours Editorial Board","year":"2020"},{"key":"10.1136\/ijgc-2023-004610_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/PGP.0000000000000566","article-title":"Intratumoral heterogeneity accounts for apparent progression of noninvasive serous tumors to invasive low-grade serous carcinoma: a study of 30 low-grade serous tumors of the ovary in 18 patients with peritoneal carcinomatosis","volume":"39","author":"Seidman","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/PAS.0000000000000824","article-title":"Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases","volume":"41","author":"Vang","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdt430","article-title":"Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary","volume":"25","author":"Uzan","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Nickles Fader","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004610_bb0060","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D","article-title":"Ovarian serous borderline tumors with invasive peritoneal implants","volume":"82","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0065","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00000478-200104000-00001","article-title":"Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas","volume":"25","author":"Bell","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0075","year":"2014"},{"key":"10.1136\/ijgc-2023-004610_bb0080","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"29","author":"Colombo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0085","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D","article-title":"Serous borderline tumors of the ovary with noninvasive peritoneal implants","volume":"83","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0090","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","article-title":"The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent","volume":"30","author":"Silva","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0095","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdg173","article-title":"Prognostic factors for patients with advanced stage serous borderline tumours of the ovary","volume":"14","author":"Morice","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00004347-199304000-00006","article-title":"The behavior of serous tumors of low malignant potential: are they ever malignant?","volume":"12","author":"Kurman","year":"1993","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PGP.0b013e31824ae6f2","article-title":"Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases","volume":"31","author":"Garg","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0110","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PAS.0b013e31802cbbe9","article-title":"The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis","volume":"31","author":"Dehari","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0115","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/his.13796","article-title":"Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa","volume":"74","author":"Murali","year":"2019","journal-title":"Histopathology"},{"key":"10.1136\/ijgc-2023-004610_bb0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.pgp.0000130049.19643.f6","article-title":"Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases","volume":"23","author":"Parker","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00004347-199107000-00010","article-title":"Ovarian serous tumor with mural nodules of carcinomatous derivation (sarcomatoid carcinoma): report of a case","volume":"10","author":"Rosa","year":"1991","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0130","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/annonc\/mdw085","article-title":"Low-grade serous carcinoma of the ovary or peritoneum","volume":"27(Suppl 1)","author":"Gershenson","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0140","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.neo.2019.03.014","article-title":"Loss of 1p36.33 frequent in low-grade serous ovarian cancer","volume":"21","author":"Van Nieuwenhuysen","year":"2019","journal-title":"Neoplasia"},{"key":"10.1136\/ijgc-2023-004610_bb0145","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/0008-5472.CAN-16-2224","article-title":"EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas","volume":"77","author":"Etemadmoghadam","year":"2017","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2023-004610_bb0150","doi-asserted-by":"crossref","first-page":"37663","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2023-004610_bb0155","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-08-3913","article-title":"Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas","volume":"69","author":"Kuo","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2023-004610_bb0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2017.08.021","article-title":"Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma","volume":"68","author":"Xing","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0165","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1158\/1541-7786.MCR-08-0193","article-title":"Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors","volume":"6","author":"Anglesio","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1136\/ijgc-2023-004610_bb0170","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41416-022-01897-1","article-title":"Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO group (MITO 22)","volume":"127","author":"Musacchio","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0175","first-page":"1269","article-title":"The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors","volume":"58","author":"C\u00eerstea","year":"2017","journal-title":"Rom J Morphol Embryol"},{"key":"10.1136\/ijgc-2023-004610_bb0180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0185","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e318229449f","article-title":"Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis","volume":"35","author":"Kurman","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0190","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ygyno.2017.09.029","article-title":"Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium","volume":"147","author":"Qiu","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0195","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/PAS.0b013e318212ae22","article-title":"The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer","volume":"35","author":"King","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0200","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0205","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004610_bb0215","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0220","author":"National Comprehensive Cancer Network","year":"2023","journal-title":"NCCN Guidelines: Ovarian cancer\/Fallopian tube cancer\/primary peritoneal cancer. Version 2"},{"key":"10.1136\/ijgc-2023-004610_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0230","article-title":"Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression","volume":"6","author":"Cheasley","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0235","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0240","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2023-004610_bb0245","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/his.13071","article-title":"Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma","volume":"70","author":"McIntyre","year":"2017","journal-title":"Histopathology"},{"key":"10.1136\/ijgc-2023-004610_bb0250","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"key":"10.1136\/ijgc-2023-004610_bb0255","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1136\/ijgc-2023-004610_bb0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41523-022-00424-y","article-title":"Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR","volume":"8","author":"Ahn","year":"2022","journal-title":"Npj Breast Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-020-1246-5","article-title":"ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis","volume":"22","author":"Zundelevich","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1136\/ijgc-2023-004610_bb0270","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2019.04.010","article-title":"Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies","volume":"154","author":"Gaillard","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0275","article-title":"Targeted next-generation sequencing reveals clinically actionable BRAF and ESR1 mutations in low-grade serous ovarian carcinoma","volume":"2018","author":"Stover","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0280","author":"United States Food and Drug Administration","year":"2022","journal-title":"Rare diseases at FDA"},{"key":"10.1136\/ijgc-2023-004610_bb0285","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ygyno.2019.06.014","article-title":"Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: an analysis of five prospective phase II\/III trials of NOGGO metadata base","volume":"154","author":"Canaz","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0290","author":"National Cancer Institute Surveillance, Epidemiology, and End Results Program","year":"2022","journal-title":"Cancer STAT facts: ovarian cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0295","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004610_bb0300","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2010.10.033","article-title":"Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?","volume":"120","author":"Vineyard","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0305","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2017.01.002","article-title":"Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study","volume":"144","author":"Rasmussen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0310","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology\/Gynecologic Oncology Group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004610_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4242-8","article-title":"Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers","volume":"18","author":"Le Page","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0320","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0325","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-982","article-title":"Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas","volume":"14","author":"Tone","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0330","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0335","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2013.11.016","article-title":"The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a Gynecologic Oncology Group study","volume":"132","author":"Fader","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0340","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/IGC.0000000000000109","article-title":"Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer","volume":"24","author":"Previs","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0345","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00404-020-05580-9","article-title":"Does lymph node ratio have any prognostic significance in maximally cytoreduced node-positive low-grade serous ovarian carcinoma?","volume":"302","author":"Aslan","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2023-004610_bb0355","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.humpath.2018.10.020","article-title":"Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network","volume":"85","author":"Sehouli","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2023-004610_bb0360","doi-asserted-by":"crossref","first-page":"558932","DOI":"10.3389\/fonc.2020.558932","article-title":"The prognostic relevance of the proliferation markers Ki-67 and Plk1 in early-stage ovarian cancer patients with serous, low-grade carcinoma based on mRNA and protein expression","volume":"10","author":"R\u00f6del","year":"2020","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0365","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00261-020-02847-2","article-title":"Diagnostic performance of PET\/CT and PET\/MR in the management of ovarian carcinoma - a literature review","volume":"46","author":"Virarkar","year":"2021","journal-title":"Abdom Radiol"},{"key":"10.1136\/ijgc-2023-004610_bb0370","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.crad.2020.03.006","article-title":"Does dual-energy CT differentiate benign and malignant ovarian tumours?","volume":"75","author":"Elsherif","year":"2020","journal-title":"Clin Radiol"},{"key":"10.1136\/ijgc-2023-004610_bb0375","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.crad.2021.04.004","article-title":"Application of contrast-enhanced dual-energy spectral CT for differentiating borderline from malignant epithelial ovarian tumours","volume":"76","author":"Han","year":"2021","journal-title":"Clin Radiol"},{"key":"10.1136\/ijgc-2023-004610_bb0380","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","article-title":"Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-fluoro-17-estradiol PET\/CT","volume":"56","author":"van Kruchten","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1136\/ijgc-2023-004610_bb0385","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jso.26450","article-title":"Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: a multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001)","volume":"123","author":"Vatansever","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0390","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0395","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/ijgc-2020-001775","article-title":"Fertility preservation in rare ovarian tumors","volume":"31","author":"Chelariu-Raicu","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0400","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.04.018","article-title":"Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers","volume":"116","author":"Rousset-Jablonski","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0405","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1210\/jc.2006-0962","article-title":"Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy","volume":"91","author":"Oktay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/ijgc-2023-004610_bb0410","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/09513590.2016.1177013","article-title":"Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes","volume":"32","author":"Pereira","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"10.1136\/ijgc-2023-004610_bb0415","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0420","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004610_bb0425","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004610_bb0430","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0435","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0440","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2020.01.021","article-title":"Low-grade serous carcinoma (LGSC): a Canadian multicenter review of practice patterns and patient outcomes","volume":"157","author":"Scott","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0445","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/JCO.2022.40.16_suppl.5522","article-title":"A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0450","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0455","author":"Clinicaltrials.gov","year":"2022","journal-title":"Letrozole with or without paclitaxel and carboplatin in treating patients with stage II-IV ovarian, Fallopian tube, or primary peritoneal cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0460","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004610_bb0465","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13940","article-title":"Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer","volume":"3","author":"Lei","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2023-004610_bb0470","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ygyno.2020.09.022","article-title":"Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States","volume":"159","author":"Charo","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0475","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0480","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.10789","article-title":"Recurrent micropapillary serous ovarian carcinoma","volume":"95","author":"Bristow","year":"2002","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0485","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2021.10.080","article-title":"Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: a systematic review and meta-analysis","volume":"164","author":"Goldberg","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0490","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0495","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2023.06.466","article-title":"GOG 3026 a phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, Fallopian tube or peritoneum (LGSOC): a GOG Foundation Study","author":"Slomovitz","year":"2023"},{"key":"10.1136\/ijgc-2023-004610_bb0505","author":"Clinicaltrials.gov","year":"2023","journal-title":"A study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors (BOUQUET)"},{"key":"10.1136\/ijgc-2023-004610_bb0510","author":"Clinicaltrials.gov","year":"2023","journal-title":"A study of avutometinib (VS-6766) v. avutometinib (VS-6766) + defactinib in recurrent low-grade serous ovarian cancer with and without a KRAS mutation (RAMP-201)"},{"key":"10.1136\/ijgc-2023-004610_bb0515","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5613","article-title":"PERCEPTION: phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer: a NOGGO trial","volume":"40","author":"Grabowski","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0520","author":"Clinicaltrials.gov","year":"2022","journal-title":"Study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer (PERCEPTION)"},{"key":"10.1136\/ijgc-2023-004610_bb0525","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1200\/JCO.2022.40.16_suppl.5572","article-title":"Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: the French Acs\u00e9 Pembrolizumab study from Unicancer","volume":"40","author":"Ray-Coquard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0530","author":"Clinicaltrials.gov","year":"2023","journal-title":"Secured access to pembrolizumab for patients with selected rare cancer types (Acs\u00e9)"},{"key":"10.1136\/ijgc-2023-004610_bb0535","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0540","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma","volume":"22","author":"Daud","year":"2017","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2023-004610_bb0545","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1136\/ijgc-2023-004610_bb0550","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"key":"10.1136\/ijgc-2023-004610_bb0555","author":"National Comprehensive Cancer Network","year":"2022","journal-title":"NCCN Guidelines: Clinical practice guidelines in oncology. Survivorship. Version 1"},{"key":"10.1136\/ijgc-2023-004610_bb0560","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.713700","article-title":"Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management","volume":"12","author":"Hyder","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1136\/ijgc-2023-004610_bb0570","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/OP.20.00113","article-title":"Management of aromatase inhibitor-induced musculoskeletal symptoms","volume":"16","author":"Gupta","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1136\/ijgc-2023-004610_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0580","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.34753","article-title":"Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies","volume":"129","author":"Manning-Geist","year":"2023","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0585","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0590","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0595","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/ijgc-2018-000018","article-title":"Low grade serous ovarian carcinoma: identifying variations in practice patterns","volume":"29","author":"Siemon","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004610_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.970918","article-title":"Advanced low grade serous ovarian cancer: a retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers","volume":"12","author":"Di Lorenzo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004610_bb0605","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.6004\/jnccn.2016.0124","article-title":"Principles of treatment for borderline, micropapillary serous, and low-grade ovarian cancer","volume":"14","author":"Hacker","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2023-004610_bb0610","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-2040-8","article-title":"Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria","volume":"470","author":"Hauptmann","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1136\/ijgc-2023-004610_bb0615","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004610_bb0620","year":"2022"},{"key":"10.1136\/ijgc-2023-004610_bb0625","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1136\/ijgc-2023-004610_bb0630","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gore.2018.05.011","article-title":"Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment","volume":"25","author":"Han","year":"2018","journal-title":"Gynecol Oncol Rep"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401689X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401689X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:40:16Z","timestamp":1753101616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2401689X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":125,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1048891X2401689X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004610","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}